## Matthew R Farren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/244293/publications.pdf

Version: 2024-02-01

22 papers 1,059 citations

16 h-index 713466 21 g-index

23 all docs

23 docs citations

23 times ranked 2215 citing authors

#	Article	IF	CITATIONS
1	Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. Journal of Clinical Investigation, 2013, 123, 4464-4478.	8.2	261
2	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 2016, 24, 1150-1158.	8.2	114
3	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Cancer Research, 2017, 77, 2647-2660.	0.9	113
4	Systemic Immune Activity Predicts Overall Survival in Treatment-NaÃ-ve Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 2565-2574.	7.0	80
5	Circulating monocyte chemoattractant proteinâ€1 (MCPâ€1) is associated with cachexia in treatmentâ€naÃ⁻ve pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 358-368.	7.3	73
6	CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif. Journal of Immunology, 2015, 194, 4717-4728.	0.8	56
7	Stressful Presentations: Mild Cold Stress in Laboratory Mice Influences Phenotype of Dendritic Cells in NaÃ-ve and Tumor-Bearing Mice. Frontiers in Immunology, 2014, 5, 23.	4.8	49
8	Tumor-Induced STAT3 Signaling in Myeloid Cells Impairs Dendritic Cell Generation by Decreasing PKCβII Abundance. Science Signaling, 2014, 7, ra16.	3.6	45
9	Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function. Scientific Reports, 2019, 9, 5068.	3.3	40
10	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Molecular Cancer Therapeutics, 2017, 16, 344-356.	4.1	31
11	Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI Insight, 2020, 5, .	5.0	31
12	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 150-160.	4.1	30
13	Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunologic Research, 2010, 46, 165-176.	2.9	26
14	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology, 2019, 19, 80-87.	1.1	24
15	Inhibiting heat shock protein 90 and the ubiquitinâ€proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. Cancer, 2017, 123, 4924-4933.	4.1	20
16	Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer. Cancer, 2020, 126, 3360-3371.	4.1	18
17	The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Molecular Cancer Therapeutics, 2017, 16, 417-427.	4.1	16
18	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunology, Immunotherapy, 2021, 70, 3337-3348.	4.2	16

#	Article	IF	CITATIONS
19	Autocrine GM-CSF transcription in the leukemic progenitor cell line KG1a is mediated by the transcription factor ETS1 and is negatively regulated through SECTM1 mediated ligation of CD7. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1004-1013.	2.4	4
20	Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 485-498.	3.4	4
21	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. British Journal of Cancer, 2020, 123, 1377-1386.	6.4	4
22	Correlation of changes in lean muscle weight with outcome in metastatic pancreatic adenocarcinoma (mPDAC) who undergo taxane-based chemotherapy (CT) Journal of Clinical Oncology, 2015, 33, e15243-e15243.	1.6	0